A randomized controlled trial of pegylated-interferon alpha-2b plus ribavirin vs interferon

被引：1
|
作者：
Pol, S [1 ]
Perronne, C [1 ]
Carrat, F [1 ]
Banisadr, F [1 ]
Morand, P [1 ]
Lunel, F [1 ]
Rosenthal, E [1 ]
机构：
[1] ANRS HC02, Paris, France
来源：
JOURNAL OF HEPATOLOGY | 2003年 / 38卷
关键词：
D O I：
10.1016/S0168-8278(03)80508-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
92
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [31] Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial
    Carrat, F
    Bani-Sadr, F
    Pol, S
    Rosenthal, E
    Lunel-Fabiani, F
    Benzekri, A
    Morand, P
    Goujard, C
    Pialoux, G
    Piroth, L
    Salmon-Céron, D
    Degott, C
    Cacoub, P
    Perronne, C
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23): : 2839 - 2848
  • [32] Efficacy and safety of pegylated interferon alpha-2b and ribavirin in chronic hepatitis C in children
    Kups-Rzepecka, Joanna
    Golabek, Violetta
    Kicinski, Przemyslaw
    Wozniakowska-Gesicka, Teresa
    PRZEGLAD GASTROENTEROLOGICZNY, 2010, 5 (06): : 341 - 348
  • [33] Cost-effectiveness of peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C
    Siebert, U
    Sroczynski, G
    Rossol, S
    Wasem, J
    Ravens-Sieberer, U
    Kurth, BM
    Manns, MP
    Hutchison, JG
    Wong, JB
    JOURNAL OF HEPATOLOGY, 2002, 36 : 129 - 130
  • [34] Prediction of Effect of Pegylated Interferon Alpha-2b plus Ribavirin Combination Therapy in Patients with Chronic Hepatitis C Infection
    Takayama, Tetsuro
    Ebinuma, Hirotoshi
    Tada, Shinichiro
    Yamagishi, Yoshiyuki
    Wakabayashi, Kanji
    Ojiro, Keisuke
    Kanai, Takanori
    Saito, Hidetsugu
    Hibi, Toshifumi
    PLOS ONE, 2011, 6 (12):
  • [35] Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues - Reply
    Kamal, Sanaa
    Schardell, Michelle
    El Kamary, Samer
    Hashem, Mohamed
    Mansour, Hoda
    Ibrahim, Amany Sayed
    HEPATOLOGY, 2008, 47 (05) : 1793 - 1794
  • [36] Reduction of hepatocellular carcinoma recurrence by pegylated interferon alpha-2b plus ribavirin treatment for chronic hepatitis C patients
    Furusyo, N.
    Murata, M.
    Ogawa, E.
    Nomura, H.
    Hayashi, J.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 : S130 - S130
  • [37] A MULTICENTER, RANDOMIZED TRIAL OF COMBINATION PEGYLATED INTERFERON-ALPHA 2A PLUS RIBAVIRIN VS. PEGYLATED INTERFERON-ALPHA 2A MONOTHERAPY IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HEPATITIS C
    Gane, Edward J.
    Strasser, Simone I.
    Crowford, Darrell H.
    Ring, John A.
    Rizkalla, Bishoy
    Thompson, Sandra J.
    McCaughan, Geoffrey W.
    HEPATOLOGY, 2009, 50 (04) : 393A - 394A
  • [38] A randomized trial of pegylated interferon alpha-2b and ribavirin vs. pegylated interferon alone in patients with chronic hepatitis C who have failed standard therapy. Interim results after 24 weeks.
    Bornstein, JD
    Muir, AJ
    Killenberg, PG
    HEPATOLOGY, 2001, 34 (04) : 589A - 589A
  • [39] Comparative Effects of Interferon Alpha-2b and Pegylated Interferon Alpha-2b on Menstrual Cycles and Ovarian Hormones in Cynomolgus Monkeys
    Enright, Brian P.
    Compton, David R.
    Collins, Nathaniel
    Davis, Thomas
    McIntyre, Barry S.
    BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2009, 86 (01) : 29 - 39
  • [40] A randomized trial of pegylated interferon alpha-2b and ribavirin vs. pegylated interferon alone in patients with chronic hepatitis C who have-failed standard therapy. Interim results after 24 weeks
    Bornstein, JD
    Muir, AJ
    Killenberg, PG
    GASTROENTEROLOGY, 2002, 123 (01) : 77 - 77
12345